Cor Vasa 2022, 64(1):53-59 | DOI: 10.33678/cor.2021.124

Efficacy and safety of endocardial radiofrequency catheter ablation of interventricular septal hypertrophy in the treatment of hypertrophic obstructive cardiomyopathy

Katarína Doležalováa, b, František Lehára, b, Jiří Ježa, b, Martin Pešla, b, c, Filip Součeka, b, Zdeněk Stáreka, b
a International Clinical Research Center, St. Anne's University Hospital Brno, Brno
b 1st Department of Internal Medicine - Cardioangiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital Brno, Brno
c Department of Biology, Faculty of Medicine, Masaryk University, Brno

Hypertrophic obstructive cardiomyopathy is characterized by abnormal thickening or enlargement of the left ventricular myocardium mass of non-dilated left ventricle not explained solely by loading conditions and presence of obstruction in outflow tract of left ventricle. Surgical septal myectomy was the first choice method of invasive treatment of septal hypertrophy in the past which was replaced by alcohol septal abla- tion in the nineties of the 20th century and nowadays it is still worldwide used, safe, and effective method in reduction of septal hypertrophy. This review introduces and describes new method in invasive reduction of septal hypertrophy which is endo- cardial radiofrequency ablation of septal hypertrophy. Our review summarizes all so far published studies and compares this new method with other methods of invasive reduction of septal hypertrophy. Endocardial radiofrequency ablation of septal hypertrophy seems to be comparably safe and effective in comparison to alcohol septal ablation with comparable decrease of left ventricle outflow tract gradient and also subjective improvement of a patient characterized by NYHA class.

Keywords: Alcohol septal ablation, Endocardial radiofrequency ablation of septal hypertrophy, Functional NYHA class improvement, Hypertrophic obstructive cardiomyopathy, Left ventricle outflow tract gradient

Received: August 31, 2021; Revised: October 22, 2021; Accepted: November 8, 2021; Published: February 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležalová K, Lehár F, Jež J, Pešl M, Souček F, Stárek Z. Efficacy and safety of endocardial radiofrequency catheter ablation of interventricular septal hypertrophy in the treatment of hypertrophic obstructive cardiomyopathy. Cor Vasa. 2022;64(1):53-59. doi: 10.33678/cor.2021.124.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathyof the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779. Go to original source... Go to PubMed...
    2. Maron BJ, Maron MS, Semsarian C. Genetics of Hypertrophic Cardiomyopathy After 20 Years. J Am Coll Cardiol 2012;60:705-715. Go to original source... Go to PubMed...
    3. Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol 2016;13:651-675. Go to original source... Go to PubMed...
    4. Shah JS, Esteban MTT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008;94:1288-1294. Go to original source... Go to PubMed...
    5. Braunwald E, Seidman Christine E, Sigwart U. Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy. Circulation 2002;106:1312-1316. Go to original source... Go to PubMed...
    6. Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Ann Intern Med 2019;170:741. Go to original source... Go to PubMed...
    7. Menon SC, Ackerman MJ, Ommen SR, et al. Impact of Septal Myectomy on Left Atrial Volume and Left Ventricular Diastolic Filling Patterns: An Echocardiographic Study of Young Patients with Obstructive Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2008;21:684-688. Go to original source... Go to PubMed...
    8. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol 2015;65:1915-1928. Go to original source... Go to PubMed...
    9. Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 1995;110:195-206; discussion 206-208. Go to original source... Go to PubMed...
    10. Yu EHC, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000;36:2219-2225. Go to original source... Go to PubMed...
    11. Stassano P, Di Tommaso L, Triggiani D, et al. Mitral Valve Replacement and Limited Myectomy for Hypertrophic Obstructive Cardiomyopathy. Tex Heart Inst J 2004;31:137-142.
    12. European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA), Brignole M, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070-1118. Go to PubMed...
    13. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214. Go to original source... Go to PubMed...
    14. Veselka J, Krejčí J, Tomašov P, Zemánek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J 2014;35:2040-2045. Go to original source... Go to PubMed...
    15. Lawrenz T, Lieder F, Bartelsmeier M, et al. Predictors of Complete Heart Block After Transcoronary Ablation of Septal Hypertrophy: Results of a Prospective Electrophysiological Investigation in 172 Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2007;49:2356-2363. Go to original source... Go to PubMed...
    16. Veselka J, Procházková Š, Duchoňová R, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv 2004;63:231-235. Go to original source... Go to PubMed...
    17. Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 2016;37:1517-1523. Go to original source... Go to PubMed...
    18. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;58:e212-e260.
    19. Sorajja P, Ommen SR, Holmes DR, et al. Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. Circulation 2012;126:2374-2380. Go to original source... Go to PubMed...
    20. Faber L, Seggewiss H, Welge D, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004;5:347-355. Go to original source... Go to PubMed...
    21. Keane D, Hynes B, King G, et al. Feasibility Study of Percutaneous Transvalvular Endomyocardial Cryoablation for the Treatment of Hypertrophic Obstructive cardiomyopathy. J Invasive Cardiol 2007;19:247-251. Go to PubMed...
    22. Schäfer U, Kreidel F, Frerker C. MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Heart Lung Circ 2014;23:e131-e135. Go to original source... Go to PubMed...
    23. Nazer B, Gerstenfeld EP, Hata A, et al. Cardiovascular applications of therapeutic ultrasound. J Interv Card Electrophysiol 2014;39:287-294. Go to original source... Go to PubMed...
    24. Rong S, Woo K, Zhou Q, et al. Septal Ablation Induced by Transthoracic High-Intensity Focused Ultrasound in Canines. J Am Soc Echocardiogr 2013;26:1228-1234. Go to original source... Go to PubMed...
    25. Liu F, Fu J, Hsi D, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Interventricular Septal Reduction: An Ovine Model with 1-Year Outcomes. Cardiology 2020;145:53-62. Go to original source... Go to PubMed...
    26. Liu L, Li J, Zuo L, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2018;72:1898-1909. Go to original source... Go to PubMed...
    27. Lawrenz T, Kuhn H. Endocardial radiofrequency ablation of septal hypertrophy: A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy. Z Kardiol 2004;93:493-499. Go to original source... Go to PubMed...
    28. Lawrenz T, Borchert B, Leuner C, et al. Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2011;57:572-576. Go to original source... Go to PubMed...
    29. Emmel M, Sreeram N, deGiovanni JV, Brockmeier K. Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood. Z Kardiol 2005;94:699-703. Go to original source... Go to PubMed...
    30. Sreeram N, Emmel M, de Giovanni JV. Percutaneous Radiofrequency Septal Reduction for Hypertrophic Obstructive Cardiomyopathy in Children. J Am Coll Cardiol 2011;58:2501-2510. Go to original source... Go to PubMed...
    31. Shelke AB, Menon R, Kapadiya A, et al. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Indian Heart J 2016;68:618-623. Go to original source... Go to PubMed...
    32. Cooper RM, Shahzad A, Hasleton J, et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation. Europace 2016;18:113-120. Go to original source... Go to PubMed...
    33. Crossen K, Jones M, Erikson C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm 2016;13:1885-1890. Go to original source... Go to PubMed...
    34. Beaser AD, Sobacki J, Aziz Z, et al. Targeted radiofrequency septal ablation to reduce outflow tract gradient in symptomatic hypertrophic obstructive cardiomyopathy: initial feasibility cohort. Heart Rhythm 2018;15:S644-S645.
    35. Peigh G, Wasserlauf J, Choudhury L, et al. From 100 to 0. JACC Case Rep 2020;2:1173-1177. Go to original source... Go to PubMed...
    36. Agarwal S, Tuzcu EM, Desai MY, et al. Updated Meta- -Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2010;55:823-834. Go to original source... Go to PubMed...
    37. Nguyen A, Schaff HV, Hang D, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score-matched cohort. J Thorac Cardiovasc Surg 2019;157:306.e3-315.e3. Go to original source... Go to PubMed...
    38. Maron BJ. Hypertrophic Cardiomyopathy. Circulation 2002;106:2419-2421. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes